News

VIDEO: Exploring SYMPLICITY’s failure, Part 2


 

AT ACC 14

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

Hypertensive retinopathy predicts stroke risk
MDedge Neurology
NHLBI hands off hypertension guidelines to ACC, AHA
MDedge Neurology
European hypertension guidelines help fill U.S. void
MDedge Neurology
'JNC 8' guideline follows convoluted endgame
MDedge Neurology
Former JNC 8 hypertension panel issues minority report
MDedge Neurology
Intensive BP, lipid control didn’t alter cognitive decline in type 2 diabetes
MDedge Neurology
New stroke guidelines focus on women’s risks
MDedge Neurology
Systolic variability after intracerebral hemorrhage raises odds of death, disability
MDedge Neurology
VIDEO: What explains SYMPLICITY HTN-3’s failure?
MDedge Neurology
Ineffective renal denervation blamed for trial’s failure
MDedge Neurology

Related Articles